serplulimab   Click here for help

GtoPdb Ligand ID: 13796

Synonyms: HANSIZHUANG® (China) | Hetronifly® | HLX-10 | HLX10
Approved drug Immunopharmacology Ligand
serplulimab is an approved drug
Compound class: Antibody
Comment: Serplulimab (HLX10) is a humanized IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody [1]. It is designed to block the inhibitory PD-1/PD-L1/2 immune checkpoint and restore T cell-mediated anti-tumour immunity.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Issafras H, Fan S, Tseng CL, Cheng Y, Lin P, Xiao L, Huang YJ, Tu CH, Hsiao YC, Li M et al.. (2021)
Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
PLoS One, 16 (12): e0257972. [PMID:34972111]